ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?

ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.

Related Keywords

Texas ,United States ,Massachusetts ,Boston ,Ohio ,Houston ,Baylor College Of Medicine ,Christiem Ballantyne ,Pamela Morris ,Vijay Nambi ,C Michael Gibson ,Steve Nissen ,University Of South Carolina ,Morris ,Harvard Medical School ,Gibson ,American College Of Cardiology ,American College ,Scientific Sessions ,New England Journal ,Medical University ,South Carolina ,Cholesterol Efflux ,Baylor College ,Primary Composite Endpoint ,Patients With Baseline ,Medscape Cardiology ,Cleveland Clinic ,Lipids ,Ipid Management ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,Cardiovascular Risk Management ,Stroke Cerebrovascular Accident Cva ,Thromboembolism ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Coronary Artery Disease ,High Density Lipoprotein Cholesterol ,